文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

局限期前列腺癌3次分割SBRT后1年毒性

Toxicity at 1 Year After Stereotactic Body Radiation Therapy in 3 Fractions for Localized Prostate Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2021-03-19

这项前瞻性多中心2期毒性研究纳入低至 favorable 中危前列腺癌患者,处方40 Gy分3次隔日照射, urethra 最高剂量限33 Gy;1年时无患者持续≥2级泌尿生殖毒性,急性≥2级GU毒性11.9%,结论认为3次分割SBRT的1年毒性可接受。

要点

  • 3次分割SBRT处方40 Gy,尿道最高剂量限33 Gy,膀胱充盈经导尿管控制。
  • 1年时无患者持续治疗相关≥2级GU毒性,拒绝原假设。
  • 急性≥2级GU毒性11.9%、3级1.7%,急性GI毒性偶发且轻。

核心结论

  • 治疗12个月后,3次分割SBRT的毒性谱可接受。

研究设计与样本

  • 前瞻性、多中心2期毒性研究,纳入低至favorable中危局限期前列腺癌患者,3家机构共59例。
  • 模拟定位前放置3–4枚基准标记及直肠间隔物,仅前列腺靶区处方40 Gy,尿道最高剂量限33 Gy为计划最高优先级。
  • 隔日治疗,毒性按CTCAE前瞻性评分并收集多项患者报告结局,1年≥2级GU毒性最大允许 prevalence 设为15%并据此确定样本量。

主要发现

  • 急性GI毒性偶发且轻,11.9%患者发生急性2级GU毒性,1.7%发生急性3级GU毒性。
  • SBRT后12个月无患者存在持续治疗相关≥2级GU毒性,原假设被拒绝。
  • 12个月时IPSS与ICIQ-SF评分较基线出现临床相关恶化。
  • 计划时所有选定的膀胱剂量/体积指标与12个月ICIQ-SF恶化强相关,而IPSS与膀胱剂量指标相关性仅为边缘。

关键数值与推荐

  • 1年≥2级GU毒性最大允许 prevalence 设为15%。
  • 前列腺靶区处方40 Gy分3次,尿道最高剂量限33 Gy。
  • 计划时对膀胱设定较不严格的目标,膀胱充盈通过Foley导尿管控制。

临床怎么用

  • 对低至favorable中危局限期前列腺癌可考虑3次分割SBRT,但需严格限制尿道最高剂量并控制膀胱充盈。
  • 计划时应关注膀胱剂量/体积指标,因其与12个月ICIQ-SF恶化强相关。
  • 治疗后12个月需随访IPSS与ICIQ-SF,关注患者报告的下尿路症状与尿失禁相关恶化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess the toxicity profile of prostate cancer stereotactic body radiation therapy (SBRT) in 3 fractions. METHODS AND MATERIALS: This was a prospective, multicenter phase 2 toxicity study enrolling patients with low to favorable intermediate-risk prostate cancer. Before simulation, 3 to 4 fiducial markers along with a rectal spacer were placed. The target (prostate only) was prescribed 40 Gy, whereas the maximum dose to the urethra was limited to 33 Gy with the highest priority at planning; less stringent objectives were placed on the bladder, the filling of which was controlled via a Foley catheter. Treatment was delivered every other day. Toxicity was prospectively scored with Common Terminology Criteria for Adverse Events, and several patient-reported outcomes were collected. The maximum allowed prevalence rate of grade 2+ genitourinary (GU) toxicity at 1 year was set at 15%, and the study was sized accordingly. RESULTS: Between November 2015 and May 2019, 59 patients were enrolled by 3 participating institutions. Acute gastrointestinal toxicity was occasional and mild, whereas 11.9% of patients developed acute grade 2 GU toxicity and 1.7% developed acute grade 3 GU toxicity. No patient had persistent treatment-related grade 2+ GU toxicity at 12 months after SBRT; thus, the null hypothesis was rejected. We observed a clinically relevant worsening of both International Prostate Symptom Score (IPSS) and International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF) scores at 12 months compared with baseline. Moreover, we found a strong association between all selected bladder dose/volume metrics at planning and ICIQ-SF worsening at 12 months, whereas for the IPSS, the correlation with bladder dose metrics was marginal. CONCLUSIONS: The results suggest that at 12 months after treatment, the toxicity profile of SBRT in 3 fractions is acceptable.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Magli A, Farneti A, Faiella A, et al. Toxicity at 1 Year After Stereotactic Body Radiation Therapy in 3 Fractions for Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2021. PMID: 33745951. doi:10.1016/j.ijrobp.2021.03.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。